PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY

以患者为中心的皮肤肿瘤学研究

基本信息

  • 批准号:
    6632599
  • 负责人:
  • 金额:
    $ 11.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-07-01 至 2005-06-30
  • 项目状态:
    已结题

项目摘要

This is a Midcareer Investigator Award in Patient-Oriented Research (POR) application (K24) for Stuart R. Lessin, M.D and will focus on cutaneous oncology. Dr. Lessin is Associate Professor and Co-Director of the Cutaneous Lymphoma Program in the Department of Dermatology at the University of Pennsylvania. He is highly committed to POR and has a well established track record (funding and publications) in the area of cutaneous T-cell lymphoma (CTCL). He has developed techniques for the molecular diagnosis of lymphoproliferative skin diseases based on T-cell receptor (TCR) gene expression and translated them into new strategies of therapy utilizing the TCR as a target. Dr. Lessin is currently the principal investigator of a FDA funded Phase I clinical trial testing the safety and efficacy of genetic (DNA) vaccination of human TCR in patients with CTCL. The overall research goal of this proposal will be to develop and test novel therapeutic approaches to skin cancers utilizing the technologies of therapeutic DNA vaccines, peptide vaccines and peptidomimetics. Dr. Lessin has been heavily involved in the mentoring and training of trainees in POR at all levels - medical students, residents/fellows and junior faculty. This has been accomplished through a series of well established POR programs. Currently, Dr. Lessin serves as a mentor in the Department of Dermatology's Cutaneous Oncology Fellowship Program, NIH Training Grant (T32), Drug Study Unit, Derm 800 Research elective and Junior Faculty Mentor's Program. The University of Pennsylvania's commitment and ability to provide opportunities and facilities necessary for POR is extraordinary. A well established Core Curriculum in POR Training, a NIH sponsored General Clinical Research Center (GCRC) and outstanding interaction between basic and clinical investigators provides a unique and dynamic environment in which to conduct and train individuals in POR. Dr. Lessin will participate in the POR core curriculum and the GCRC. This award will provide a critical infrastructure for Dr. Lessin to pursue POR and to mentor other investigators in POR. A commitment of 50 percent effort will ensure the continued acquisition of funding and protected time for clinical testing of new therapies. Furthermore, it will enable Dr. Lessin to continue to participate in the ongoing departmental and institutional POR programs and serve as a role model and mentor for young investigators in POR at the University of Pennsylvania.
这是Stuart R. Lessin医学博士获得的面向患者的研究(POR)申请(K24)的职业中期研究者奖,将专注于皮肤肿瘤学。Lessin博士是宾夕法尼亚大学皮肤科皮肤淋巴瘤项目的副教授和联合主任。他高度致力于POR,并在皮肤t细胞淋巴瘤(CTCL)领域拥有良好的记录(资助和发表)。他开发了基于t细胞受体(TCR)基因表达的淋巴增生性皮肤病分子诊断技术,并将其转化为利用TCR作为靶点的新治疗策略。Lessin博士目前是FDA资助的一项I期临床试验的首席研究员,该试验测试了CTCL患者中人类TCR遗传(DNA)疫苗接种的安全性和有效性。本提案的总体研究目标将是开发和测试利用治疗性DNA疫苗、肽疫苗和拟肽剂技术治疗皮肤癌的新方法。Lessin博士一直积极参与指导和培训贫困地区各级受训者——医科学生、住院医生/研究员和初级教员。这是通过一系列完善的扶贫项目实现的。目前,Lessin博士在皮肤科的皮肤肿瘤学奖学金项目、NIH培训补助金(T32)、药物研究单元、皮肤病800研究选修课和青年教师导师项目中担任导师。宾夕法尼亚大学的承诺和能力,提供必要的机会和设施的贫困是非凡的。一个完善的POR培训核心课程,一个由NIH赞助的普通临床研究中心(GCRC),以及基础和临床研究人员之间的杰出互动,提供了一个独特而充满活力的环境来指导和培训POR个人。莱辛博士将参加扶贫中心核心课程和GCRC。该奖项将为莱辛博士提供关键的基础设施,以开展贫困研究并指导其他研究人员开展贫困研究。承诺付出50%的努力将确保新疗法的临床试验继续获得资金和保护时间。此外,它将使Lessin博士能够继续参与正在进行的部门和机构POR项目,并作为宾夕法尼亚大学POR年轻研究人员的榜样和导师。

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Influence of Eating at Home on Dietary Diversity and Airway Inflammation in Portuguese School-Aged Children.
Dietary Acid Load: A Novel Nutritional Target in Overweight/Obese Children with Asthma?
  • DOI:
    10.3390/nu11092255
  • 发表时间:
    2019-09-01
  • 期刊:
  • 影响因子:
    5.9
  • 作者:
    Cunha, Pedro;Paciencia, Ines;Moreira, Pedro
  • 通讯作者:
    Moreira, Pedro
The clonal nature of pityriasis lichenoides.
苔藓样糠疹的克隆性质。
  • DOI:
    10.1001/archderm.138.8.1063
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Weinberg,JeffreyM;Kristal,Leonard;Chooback,Lillian;Honig,PaulJ;Kramer,EMichael;Lessin,StuartR
  • 通讯作者:
    Lessin,StuartR
Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sezary syndrome).
皮肤 T 细胞淋巴瘤(塞扎里综合征)白血病期 T 细胞上的 CD7 表达存在差异。
  • DOI:
    10.1046/j.1523-1747.2001.01456.x
  • 发表时间:
    2001
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Vonderheid,EC;Bigler,RD;Kotecha,A;Boselli,CM;Lessin,SR;Bernengo,MG;Polansky,M
  • 通讯作者:
    Polansky,M
Contribution of flow cytometry in the diagnosis of cutaneous lymphoid lesions.
流式细胞术在皮肤淋巴病变诊断中的贡献。
  • DOI:
    10.1046/j.1523-1747.2003.12631.x
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wu,Hong;Smith,Mitchell;Millenson,MichaelM;Nicolaou,Nicos;VanDeerlin,ViviannaM;Addya,Kathkali;Lessin,Stuart;Al-Saleem,Tahseen
  • 通讯作者:
    Al-Saleem,Tahseen
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STUART R LESSIN其他文献

STUART R LESSIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STUART R LESSIN', 18)}}的其他基金

TOPICAL NITROGEN MUSTARD TREATMENT OF MYCOSIS FUNGOIDES*
局部氮芥治疗蕈样肉芽肿*
  • 批准号:
    7371092
  • 财政年份:
    2006
  • 资助金额:
    $ 11.82万
  • 项目类别:
A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Notrogen Mustard
评估 Notrogen 芥末安全性和功效的 II 期关键试验
  • 批准号:
    8135179
  • 财政年份:
    2006
  • 资助金额:
    $ 11.82万
  • 项目类别:
A phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard
评估氮芥安全性和有效性的 II 期关键试验
  • 批准号:
    7368628
  • 财政年份:
    2006
  • 资助金额:
    $ 11.82万
  • 项目类别:
TOPICAL NITROGEN MUSTARD TREATMENT OF MYCOSIS FUNGOIDES*
局部氮芥治疗蕈样肉芽肿*
  • 批准号:
    7057016
  • 财政年份:
    2006
  • 资助金额:
    $ 11.82万
  • 项目类别:
A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Notrogen Mustard
评估 Notrogen 芥末安全性和功效的 II 期关键试验
  • 批准号:
    7765826
  • 财政年份:
    2006
  • 资助金额:
    $ 11.82万
  • 项目类别:
CORE--MELANOMA FACILITY
核心——黑色素瘤设施
  • 批准号:
    6573825
  • 财政年份:
    2001
  • 资助金额:
    $ 11.82万
  • 项目类别:
CORE--MELANOMA FACILITY
核心——黑色素瘤设施
  • 批准号:
    6454184
  • 财政年份:
    2000
  • 资助金额:
    $ 11.82万
  • 项目类别:
CORE--MELANOMA FACILITY
核心——黑色素瘤设施
  • 批准号:
    6456208
  • 财政年份:
    2000
  • 资助金额:
    $ 11.82万
  • 项目类别:
CORE--MELANOMA FACILITY
核心——黑色素瘤设施
  • 批准号:
    6300086
  • 财政年份:
    2000
  • 资助金额:
    $ 11.82万
  • 项目类别:
PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY
以患者为中心的皮肤肿瘤学研究
  • 批准号:
    6171529
  • 财政年份:
    1999
  • 资助金额:
    $ 11.82万
  • 项目类别:

相似海外基金

From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
  • 批准号:
    MR/Y013050/1
  • 财政年份:
    2024
  • 资助金额:
    $ 11.82万
  • 项目类别:
    Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
  • 批准号:
    495575
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
    Operating Grants
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
  • 批准号:
    2884930
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
    Studentship
Core B: Clinical Trials Core
核心 B:临床试验核心
  • 批准号:
    10554476
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
  • 批准号:
    10761602
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
  • 批准号:
    10895949
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
  • 批准号:
    10891325
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
  • 批准号:
    10855627
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
  • 批准号:
    10758129
  • 财政年份:
    2023
  • 资助金额:
    $ 11.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了